Description

Emcure Pharmaceuticals and Landmark Global Learning submitted clarifications to BSE Surveillance Department stating no undisclosed price-sensitive information exists behind recent significant volume/price movements in their scrips.

Summary

BSE received clarifications from two listed companies — Emcure Pharmaceuticals Limited (Scrip Code: 544210) and Landmark Global Learning Limited (Scrip Code: 544341) — in response to BSE Surveillance Department queries regarding significant increases in trading volume and/or price of their respective securities. Both companies confirmed that the movements are market-driven and that there is no undisclosed price-sensitive information pending disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Points

  • Emcure Pharmaceuticals responded to BSE surveillance query ref. no. L/SURV/ONL/PV/APJ/2025-2026/961 dated March 10, 2026.
  • Emcure stated that the increase in price/volume is market-driven and beyond the company’s control.
  • Emcure confirmed no event/information requiring disclosure under Regulation 30 of SEBI Listing Regulations exists at present.
  • Landmark Global Learning (formerly Landmark Immigration Consultants Limited) responded to BSE query ref. no. L/ISURV/ONL/PV/SJ/2025-20/234614 dated March 9, 2026.
  • Landmark Global Learning also confirmed no undisclosed material information behind the significant movement in its securities.
  • Both companies reaffirmed their commitment to timely disclosure obligations.

Regulatory Changes

No regulatory changes introduced. These are routine responses to BSE surveillance queries under existing SEBI LODR framework.

Compliance Requirements

  • Listed companies are required to respond promptly to BSE Surveillance Department queries regarding abnormal price/volume movements.
  • Companies must comply with Regulation 30 of SEBI (LODR) Regulations, 2015 for timely disclosure of material events and information.
  • Emcure Pharmaceuticals: Company Secretary & Compliance Officer — Amruta Yangalwar (Membership No. A25687) signed the response.

Important Dates

  • March 9, 2026: BSE surveillance query issued to Landmark Global Learning.
  • March 10, 2026: BSE surveillance query issued to Emcure Pharmaceuticals.
  • March 10, 2026: Both companies submitted clarifications to BSE.

Impact Assessment

No material market or operational impact. These are standard surveillance disclosures confirming no undisclosed price-sensitive information. Investors should note that BSE actively monitors abnormal price/volume activity and seeks clarifications from companies. The absence of any undisclosed information reduces the risk of information asymmetry for retail investors in EMCURE (544210) and Landmark Global Learning (544341).

Impact Justification

Routine surveillance clarifications from two companies confirming no undisclosed material events; market-driven price/volume movement with no regulatory action or compliance change required.